Implications of Comparative Effectiveness Research for Health Care Innovation
Tuesday, June 15, 8:00 - 9:30AM

Comparative Effectiveness Research (CER) has become a centerpiece of US health reform and an essential tool in managing the rapidly escalating costs of new treatments and technologies. This session will convene a high-level panel to explore the drug development implications of creating a patient-centered and consumer-driven health care marketplace and outline what is required to develop and maintain a Comparative Effectiveness Research/Health Technology Assessment program with the end result of better and expedited patient care.

Jeff Goldsmtih	Judith L. Glennie	Richard Gliklich	Jack Lewin
Mark B. McClellan	Sir Michael D. Rawlins	David B. Snow, Jr.	Myrl Weinberg

KEYNOTE/MODERATOR

• Jeff Goldsmith, PhD, Associate Professor, University of Virginia; President, Health Futures, Inc., United States

PANELISTS

• Judith L. Glennie, Pharm D. MSc, Director, Strategic Health Technology Assessment (HTA), Janssen-Ortho, Inc., Canada
• Richard Gliklich, MD, President and CEO, Outcome Sciences Inc., United States
• Jack Lewin, MD, Chief Executive Officer, American College of Cardiology, United States
• Mark B. McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, Brookings Institute, United States
• Sir Michael D. Rawlins, Chairman, NICE; University of Newcastle, United Kingdom
• David B. Snow, Jr., Chairman of the Board and Chief Executive Officer, Medco Health Solutions, Inc., United States
• Myrl Weinberg, President, National Health Council, United States